REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. David F. McDermott discussing results of the phase 1/2 LITESPARK-024 study part 1 assessing ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Patrizia ...

NEO-811 is a novel molecular glue degrader intended to fully block a key clear cell renal cell carcinoma signaling pathway via cereblon-dependent target degradation. The primary outcome measures for ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ...

The cheerful Mr. Fun Computer is gone, replaced by a digital ghost corrupted by a virus from Black. Now he's infecting everything—spreading sorrow, erasing joy, and enslaving his former allies. With ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The allogenic cell therapy achieved all primary and ...

In a recent trial, 11 of 12 children treated with DB-OTO demonstrated meaningful hearing gains. New data from the Phase 1/2 CHORD trial published in The New England Journal of Medicine and presented ...

Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. The biotech, which began the phase 1/2 study in July, took the action to give it time to determine the “root cause ...